title: Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812).
abstract: BACKGROUND
  The purpose of this study was to evaluate whether radiotherapy with carboplatin would result in longer survival than radiotherapy alone in elderly patients with unresectable stage III non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Eligible patients were 71 years of age or older with unresectable stage III NSCLC. Patients were randomly assigned to the radiotherapy alone (RT) arm, irradiation with 60 Gy; or the chemoradiotherapy (CRT) arm, the same radiotherapy and additional concurrent use of carboplatin 30 mg/m(2) per fraction up to the first 20 fractions.
  
  
  RESULTS
  This study was terminated early when 46 patients were registered from November 1999 to February 2001. Four patients (one in the RT arm, three in the CRT arm) were considered to have died due to treatment-related causes. The JCOG Radiotherapy Committee assessed these treatment-related deaths (TRDs) and the compliance with radiotherapy in this trial. They found that 60% of the cases corresponded to protocol deviation and 7% were protocol violation in dose constraint to the normal lung, two of whom died due to radiation pneumonitis. As to the effectiveness for the 46 patients enrolled, the median survival time was 428 days [95% confidence interval (CI) = 212-680 days] in the RT arm versus 554 days (95% CI = 331 to not estimable) in the CRT arm.
  
  
  CONCLUSIONS
  Due to the early termination of this study, the effectiveness of concurrent use of carboplatin remains unclear. We re-planned and started a study with an active quality control program which was developed by the JCOG Radiotherapy Committee.
authors.affiliation: National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka 591-8555, Japan. s-atagi@kch.hosp.go.jp
authors.forename: Shinji
authors.initials: S
authors.lastname: Atagi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawahara
authors.forename: Tomohide
authors.initials: T
authors.lastname: Tamura
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Noda
authors.forename: Koshiro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Akira
authors.initials: A
authors.lastname: Yokoyama
authors.forename: Takahiko
authors.initials: T
authors.lastname: Sugiura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Senba
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishikura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ikeda
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishizuka
authors.forename: Nagahiro
authors.initials: N
authors.lastname: Saijo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D011658:Pulmonary Fibrosis / Q000209:etiology; D017564:Radiation Pneumonitis / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin